Civitas reports positive Phase IIb trial results of Parkinson's disease treatment

Civitas Therapeutics has released positive results from a Phase IIb clinical trial of CVT-301, an inhaled formulation of levodopa (L-dopa), being developed for the treatment of intermittent debilitating motor fluctuations (OFF episodes) associated wi…
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news